KRYS — Krystal Biotech, Inc.

KRYS Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Net Revenue: $107.1 million from VYJUVEC, marking nearly 10% growth from Q3 and approximately 18% year-over-year growth.
• Full Year 2025 Net Revenue: $389.1 million, up 34% compared to 2024.
• Gross Margin: 94% for Q4 and the full year, consistent with prior quarters.
• Operating Expenses: R&D expenses were $14.8 million, and SG&A expenses were $41.4 million, reflecting increased headcount and marketing costs.
• Net Income: $51.4 million for Q4, translating to $1.77 per basic share and $1.70 per diluted share; full-year net income was $204.8 million.
• Cash Position: Ended the year with $955.9 million in cash and investments.

2. Strategic Updates and Business Highlights

• Commercial Expansion: Significant progress in the U.S. and international markets, with a focus on expanding access to VYJUVEC. Over 20 distributor agreements signed, aiming to expand to over 40 countries in 2026.
• Product Launches: Successful launches in France and Japan, with ongoing pricing negotiations in Germany and France.
• Pipeline Development: Two registrational trials in progress for NK and ocular conditions, with plans to initiate additional trials for cystic fibrosis and other conditions later in the year.
• Innovative Dosing: Adjustments made to dosing regimens for ocular and NK treatments to facilitate home administration and improve patient compliance.

3. Forward Guidance and Outlook

• 2026 Expectations: Anticipated revenue growth driven by international expansion, particularly in Europe and Japan. Guidance for non-GAAP R&D and SG&A expenses projected to be between $175 million and $195 million.
• Clinical Development: Continued focus on advancing the pipeline with multiple data readouts expected by year-end, including for KB407 and KB801.

4. Challenges and Points of Concern

• Patient Compliance: Concerns regarding patient adherence to treatment regimens, particularly in Japan where patients face a two-week prescription renewal requirement.
• Pricing Negotiations: Ongoing negotiations in Germany and France may impact revenue recognition and growth, with potential delays in final agreements.
• Market Dynamics: Shifts in U.S. treatment patterns, with longer-tenured patients moving towards intermittent treatment cycles, complicating revenue projections.

5. Notable Q&A Insights

• Revenue Breakdown: Management indicated that while U.S. demand is growing, international markets are expected to be the primary revenue drivers in 2026.
• Dosing Regimen Changes: Adjustments to dosing schedules for ocular treatments were made to enhance patient compliance and reduce administration errors, with no changes to dosage volume.
• Stock Buyback Considerations: Management remains cautious about stock buybacks, prioritizing investments in the pipeline and awaiting clarity on larger indications before making definitive decisions.
• Patient Compliance Rates: Compliance in Europe is reportedly on par with the U.S., but there are concerns about potential drop-offs in Japan due to the prescription renewal process.

This summary encapsulates the key financial metrics, strategic initiatives, and challenges faced by Krystal Biotech, providing a comprehensive overview of their Q4 2025 performance and outlook.